Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.37 |
| ▸ | LAP3 | P28838 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 3/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334244 | 0.73 | LMNA (0.38) | FDPSLAP3LMNAMMP1MMP2 | |
| SCHEMBL322763 | 0.73 | — | — | |
| SCHEMBL28431627 | 0.70 | LMNA (0.36) | FDPSLAP3LMNA | |
| SCHEMBL21385184 | 0.70 | LMNA (0.43) | FDPSLMNAGRM4 | |
| SCHEMBL753702 | 0.70 | — | — | |
| SCHEMBL968861 | 0.70 | LMNA (0.43) | FDPSLAP3LMNA | |
| SCHEMBL23135978 | 0.67 | FDPS (0.43) | FDPSLAP3LMNAMMP1ANPEP | |
| SCHEMBL20001341 | 0.67 | FDPS (0.39) | FDPSLAP3METAP1ANPEPGRM4 | |
| SCHEMBL21671040 | 0.67 | LMNA (0.33) | FDPSLMNAGRM4 | |
| SCHEMBL9561492 | 0.65 | LAP3 (0.32) | FDPSLAP3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | FDPS 3007/4885LAP3 2665/4885LMNA 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.